Form 4: Forbion Funds Reduce Stake in NewAmsterdam Pharma Through Planned Share Sales

Forbion Capital funds executed pre-planned sales of NewAmsterdam Pharma shares, reducing their holdings slightly.

Summary

• ForGrowth NAP B.V., along with related Forbion Capital funds, sold a total of 41,803 ordinary shares of NewAmsterdam Pharma Co N.V. across two transactions.
• The sales were executed on November 15, 2024, and November 18, 2024, at weighted average prices of $25.0218 and $25.0786 per share, respectively.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. on March 28, 2024.
• The shares were sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A.
• Following these sales, ForGrowth NAP B.V. still beneficially owns 11,778,760 ordinary shares, with a portion held directly and the majority held indirectly through PoolCo.

Sentiment

Score: 5

Explanation: The document reflects routine transactions under a pre-arranged plan, with no significant positive or negative implications. The sentiment is neutral.

Negatives

• The sales by Forbion funds indicate a slight reduction in their stake in NewAmsterdam Pharma.

Risks

• Continued sales by major shareholders could potentially exert downward pressure on the stock price.
• The reliance on a pre-arranged trading plan may not reflect the current market conditions or the long-term outlook of the company.

Industry Context

This filing is a routine disclosure of share transactions by major shareholders, which is common in the pharmaceutical industry. It provides transparency into the trading activities of significant investors.

Comparison to Industry Standards

• Similar filings are common for companies with significant institutional ownership, such as those in the biotechnology and pharmaceutical sectors.
• The use of a Rule 10b5-1 trading plan is a standard practice for insiders to avoid accusations of trading on non-public information.
• Comparable companies with similar institutional ownership structures would also have similar filings when major shareholders adjust their positions.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, potentially affecting shareholders.
• The transactions do not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

NewAmsterdam Pharma, Forbion Capital, Share Sale, Rule 10b5-1, ForGrowth NAP B.V., Stock Transaction, Insider Trading